News

Nerve cells in the retina were analyzed at the Vienna University of Technology using microelectrodes. According to researchers, the nerve cells demonstrated surprisingly stable behavior, which is good news for retina implants.

The authors searched PubMed, Scopus, MEDLINE, ScienceDirect, and ClinicalTrials.gov, and selected studies based on reports with an association between RVO and heart attack risk.

ONS-5010 did not meet the pre-specified non-inferiority endpoint at week 8.

Kim served the Samsung Bioepis as Development Division Leader since December 2021.

The company begins Phase 1 trials of oral GAL-101, targeting amyloid beta aggregation. Promising safety and efficacy in ophthalmic models suggest potential for treating dry AMD, glaucoma, and neurodegenerative eye diseases.

This virtual key opinion leader (KOL) event will take place on Wednesday, December 11, 2024, at 4:00 PM ET.

EyePoint Pharmaceuticals has dosed the first patient in the LUCIA Phase 3 trial of Duravyu for wet AMD. The study evaluates Duravyu’s efficacy, durability, and re-dosing every 6 months in both treatment-naïve and previously treated patients. Topline data is anticipated in 2026.

The Foundation has assembled a multidisciplinary team of leading scientists, researchers, and physicians from multiple institutions, all focused on accelerating convergent technologies.

This service will provide researchers with tailored animal models that closely mimic human ocular conditions.

The presentation and the moderated Q&A is scheduled for Tuesday, December 3, 2024 in Presentation Room 3 at 1:30 pm ET.

Sozinibercept will be featured as part of an oral presentation at the annual FLORetina Congress being held on December 5-8, 2024 in Florence, Italy.

The organization will provide resources for spreading awareness and educating patients and care givers.

With news of several biosimilar candidates moving along the path of approval, Modern Retina is taking a moment to recap the updates on the state of these biosimilars.

A study found that a simplified artificial circuit, modeled after the brain's neuronal system, can predict network activity and provide insights into how the brain manages short-term memory, with potential implications for novel treatments of eye movement disorders.

In a study, a team of Korean researchers developed an AI model using OCT images to predict neovascular AMD treatment outcomes after anti-VEGF injections. The model highlights AI’s potential in personalized ophthalmic care.

Arshad Khanani, MD, MA, FASRS, presented positive data from the phase 2 fellow eye sub-study evaluating the subretinal delivery of ABBV-RGX-314.

The findings suggest that retinal microvessel damage may occur due to renal hypertension (RH).

Patients treated with investigational oral therapy gildeuretinol (ALK-001) showed a statistically significant reduction in the GA lesion growth rate.

The California Institute for Regenerative Medicine has funded Keck School of Medicine of USC translational research advancing a therapy for dry age-related macular degeneration, one of the leading causes of blindness in older adults.

Connell’s appointment was effective immediately after the Annual General Meeting of the Company on November 15, 2024.

Dosing in the first phase of the phase 1/2 OCU410ST GARDian trial for Stargardt disease is complete.

Avant Technologies and Ainnova Tech have partnered to develop a low-cost retinal camera integrated with Ainnova’s Vision AI platform for early detection of ocular and systemic diseases. The technology will be marketed as a SaaS platform for primary care settings.

The investigators conducted a randomized controlled trial of 60 patients who underwent monitored anesthesia care sedation for oculoplastic procedures from August 2018 to November 2020.

ABI-110 has the potential to offer a durable and effective solution by addressing the root causes of wet AMD at the genetic level.

Study participants include people with no diabetes as well as those with various stages of the condition, creating a set of information distinct from previous research.

Gupta is a nationally recognized retinal surgeon and an entrepreneur whose knowledge and experience on the phases of drug development and medical devices.